- Home
- BANL vs SABS Comparison
BANL vs SABS Comparison
Compare BANL & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANL
- SABS
- Stock Information
- Founded
- BANL 2015
- SABS 2014
- Country
- BANL Malaysia
- SABS United States
- Employees
- BANL N/A
- SABS N/A
- Industry
- BANL Oil Refining/Marketing
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BANL Energy
- SABS Health Care
- Exchange
- BANL Nasdaq
- SABS Nasdaq
- Market Cap
- BANL 17.6M
- SABS 23.9M
- IPO Year
- BANL 2023
- SABS N/A
- Fundamental
- Price
- BANL $1.05
- SABS $2.46
- Analyst Decision
- BANL
- SABS Strong Buy
- Analyst Count
- BANL 0
- SABS 5
- Target Price
- BANL N/A
- SABS $12.75
- AVG Volume (30 Days)
- BANL 52.5K
- SABS 39.8K
- Earning Date
- BANL 09-12-2024
- SABS 11-11-2024
- Dividend Yield
- BANL N/A
- SABS N/A
- EPS Growth
- BANL N/A
- SABS N/A
- EPS
- BANL N/A
- SABS N/A
- Revenue
- BANL $521,173,543.00
- SABS $2,780,084.00
- Revenue This Year
- BANL N/A
- SABS N/A
- Revenue Next Year
- BANL N/A
- SABS N/A
- P/E Ratio
- BANL N/A
- SABS N/A
- Revenue Growth
- BANL 24.34
- SABS N/A
- 52 Week Low
- BANL $0.55
- SABS $2.16
- 52 Week High
- BANL $2.14
- SABS $10.50
- Technical
- Relative Strength Index (RSI)
- BANL 69.76
- SABS 42.28
- Support Level
- BANL $0.62
- SABS $2.50
- Resistance Level
- BANL $0.68
- SABS $2.76
- Average True Range (ATR)
- BANL 0.08
- SABS 0.31
- MACD
- BANL 0.05
- SABS -0.04
- Stochastic Oscillator
- BANL 100.00
- SABS 1.07
About BANL CBL International Limited
CBL International Ltd is a company that provides a complete range of marine fuel logistics services. It sources the highest quality marine fuel from its trusted suppliers and ensures timely delivery to its customers. The company's expertise lies in providing a seamless and efficient one-stop solution for vessel refueling needs, making it a reliable partner for shipping companies. CBL International Ltd has a strong presence in China, Hong Kong, and Malaysia.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.